ADV7103
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acidosis, Renal Tubular
Conditions
Acidosis, Renal Tubular
Trial Timeline
Dec 20, 2023 → Mar 1, 2025
NCT ID
NCT03831152About ADV7103
ADV7103 is a phase 3 stage product being developed by Advicenne for Acidosis, Renal Tubular. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03831152. Target conditions include Acidosis, Renal Tubular.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07446881 | Phase 1 | Completed |
| NCT03831152 | Phase 3 | Withdrawn |
Competing Products
3 competing products in Acidosis, Renal Tubular
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Insulin (Aspart Insulin [Novolog], Regular Insulin) | Novo Nordisk | Pre-clinical | 22 |
| insulin glargine+ glulisine + NPH + Regular insulin | Sanofi | Approved | 84 |
| ADV7103 + Placebo | Advicenne | Phase 3 | 69 |